| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. | CHIEF FINANCIAL OFFICER | Common Stock | 5,000 | $4,400 | $0.8800 | 30 Nov 2023 | Direct |
| SAB Biotherapeutics, Inc. | CHIEF FINANCIAL OFFICER | Employee Stock Option (right to buy) | 115,000 | 21 Feb 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | 21 Feb 2024 | 1 | $0 | 4 | CHIEF FINANCIAL OFFICER | 23 Feb 2024, 16:45 |
| SABS | SAB Biotherapeutics, Inc. | 30 Nov 2023 | 1 | +$4,500 | 4 | CHIEF FINANCIAL OFFICER | 30 Nov 2023, 17:00 |
| SABS | SAB Biotherapeutics, Inc. | 30 Oct 2023 | 1 | $0 | 4 | CHIEF FINANCIAL OFFICER | 03 Nov 2023, 16:50 |
| SABS | SAB Biotherapeutics, Inc. | 30 Oct 2023 | 0 | $0 | 3 | CHIEF FINANCIAL OFFICER | 03 Nov 2023, 16:40 |